Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)
China · Delayed Price · Currency is CNY 22.13
+0.30 (1.37%)
Aug 26, 2026, 3:04 PM CST
SHE:002262 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 22,175 | 24,511 | 24,744 | 27,326 | 24,736 | 15,769 | |
Market Cap Growth | -13.72% | -0.94% | -9.45% | 10.47% | 56.87% | -2.01% |
Enterprise Value | 18,474 | 20,563 | 20,984 | 23,972 | 21,956 | 13,322 |
Last Close Price | 21.83 | 23.65 | 23.48 | 25.81 | 23.20 | 14.56 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 20.02 | 23.18 | 21.64 | 26.35 | 27.46 | 19.77 |
Forward PE | 16.92 | 19.46 | 18.59 | 22.41 | 24.31 | 17.58 |
PS Ratio | 3.62 | 4.15 | 4.34 | 5.42 | 5.76 | 4.01 |
PB Ratio | 2.65 | 3.05 | 3.40 | 4.26 | 4.43 | 3.22 |
P/TBV Ratio | 2.74 | 3.14 | 3.50 | 4.38 | 4.49 | 3.27 |
P/FCF Ratio | 52.63 | 38.24 | 53.09 | 43.08 | 46.39 | 31.86 |
P/OCF Ratio | 25.67 | 22.73 | 27.01 | 27.10 | 28.73 | 22.49 |
PEG Ratio | - | 1.50 | 1.09 | 1.02 | 1.35 | 1.66 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.02 | 3.48 | 3.68 | 4.76 | 5.11 | 3.39 |
EV/EBITDA Ratio | 13.55 | 16.26 | 15.38 | 19.90 | 21.43 | 13.88 |
EV/EBIT Ratio | 16.00 | 18.77 | 17.30 | 22.41 | 24.35 | 15.72 |
EV/FCF Ratio | 43.85 | 32.08 | 45.02 | 37.79 | 41.17 | 26.91 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 |
Debt / EBITDA Ratio | 0.05 | 0.05 | 0.05 | 0.09 | 0.09 | 0.11 |
Debt / FCF Ratio | 0.17 | 0.11 | 0.15 | 0.18 | 0.17 | 0.22 |
Net Debt / Equity Ratio | -0.44 | -0.49 | -0.51 | -0.53 | -0.52 | -0.52 |
Net Debt / EBITDA Ratio | -2.75 | -3.12 | -2.73 | -2.81 | -2.82 | -2.66 |
Net Debt / FCF Ratio | -8.71 | -6.16 | -7.98 | -5.33 | -5.42 | -5.16 |
Asset Turnover | 0.67 | 0.67 | 0.72 | 0.73 | 0.71 | 0.75 |
Inventory Turnover | 2.23 | 2.37 | 2.40 | 2.09 | 1.57 | 1.80 |
Quick Ratio | 5.27 | 5.18 | 5.00 | 5.64 | 4.88 | 5.01 |
Current Ratio | 6.22 | 5.92 | 5.68 | 6.46 | 5.86 | 5.93 |
Return on Equity (ROE) | 13.68% | 13.79% | 16.67% | 17.25% | 16.78% | 17.72% |
Return on Assets (ROA) | 7.88% | 7.75% | 9.62% | 9.68% | 9.25% | 10.14% |
Return on Invested Capital (ROIC) | 22.84% | 25.82% | 32.43% | 33.10% | 31.80% | 34.72% |
Return on Capital Employed (ROCE) | 13.70% | 13.50% | 16.50% | 16.40% | 15.90% | 16.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 4.95% | 4.31% | 4.62% | 3.79% | 3.64% | 5.06% |
FCF Yield | 1.90% | 2.61% | 1.88% | 2.32% | 2.16% | 3.14% |
Dividend Yield | 1.75% | 1.69% | 1.53% | 1.24% | 0.86% | 1.37% |
Payout Ratio | 36.97% | 34.63% | 28.31% | 19.54% | 22.51% | 12.63% |
Buyback Yield / Dilution | 0.56% | 0.50% | -0.53% | 0.53% | -0.22% | 0.24% |
Total Shareholder Return | 2.32% | 2.19% | 1.01% | 1.76% | 0.65% | 1.61% |